Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
64.66 USD | -0.94% | -1.20% | -23.87% |
04:51pm | Oppenheimer Adjusts Cytokinetics Price Target to $106 From $107, Maintains Outperform Rating | MT |
May. 08 | Cytokinetics Q1 Net Loss Narrows, Revenue Declines | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-23.87% | 6.84B | |
+2.87% | 108B | |
+10.01% | 105B | |
+2.10% | 23.46B | |
-11.70% | 21.72B | |
-7.05% | 18.64B | |
-38.55% | 17.45B | |
-7.40% | 17.19B | |
+6.47% | 13.99B | |
+35.69% | 12.53B |
- Stock Market
- Equities
- CYTK Stock
- News Cytokinetics, Incorporated
- Cytokinetics Insider Sold Shares Worth $461,875, According to a Recent SEC Filing